Systemic Chemotherapy
Systemic Chemotherapy - Related Videos
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
0 Views •
Cited by 28 •
2012
This abstract describes a novel method to assess the development of neurotoxicity in patients receiving chemotherapy treatment. While conventional assessment methods are limited in their ability to detect early changes in nerve function, nerve excitability techniques provide early identification of patients at risk of severe neurotoxicity and insight into pathophysiology.
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
0 Views •
Cited by 15 •
2016
The current report summarizes a protocol that can be utilized to model the influence of the bone marrow microenvironment niche on leukemic cells with emphasis placed on enrichment of the most chemoresistant subpopulation.
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
0 Views •
2025
The protocol aims to describe a mouse model for generating relapses of acute lymphoblastic leukemia, based on the dynamics of the response to induction chemotherapy.
13:19
The Use of Chemostats in Microbial Systems Biology
0 Views •
Cited by 67 •
2013
Cell growth rate is a regulated process and a primary determinant of cell physiology. Continuous culturing using chemostats enables extrinsic control of cell growth rate by nutrient limitation facilitating the study of molecular networks that control cell growth and how those networks evolve to optimize cell growth.
05:06
Alkaline Single Cell Gel Electrophoresis: A Sensitive Technique for Quantitative Estimation of DNA Damage in Individual Cancer Cells Following Chemotherapy
0 Views •
2025
In this video, we demonstrate an alkaline single-cell electrophoresis assay to quantify both single- and double-strand DNA breaks in doxorubicin-treated cells. Alkaline conditions disrupt the hydrogen bonds between DNA base pairs, resulting in the complete unwinding and separation of DNA strands. This allows differential migration of undamaged and damaged DNA fragments in agarose gel upon electrophoresis, revealing a comet-shaped structure of slowly migrating undamaged DNA forming the circular...
FAQs
These medicines can interfere with DNA replication, cell division, or DNA repair. Disrupting these processes limits a cancer cell’s ability to copy genetic material, continue dividing, or maintain DNA integrity. The relevance is that several essential growth functions become treatment targets, helping explain how chemotherapy can reduce malignant cell populations.
Healthy tissues may also be injured because some normal cells proliferate rapidly, making them vulnerable to drugs that interfere with replication, division, or repair. This shared biological feature helps account for adverse effects and makes treatment planning a balance between affecting malignant cells and limiting harm to normal fast-growing cells.
Combining medicines or changing the timing and amount of doses can be used to shape a regimen. The overview identifies drug selection, dosing schedules, and combination regimens as central planning variables. Together, these choices are considered alongside treatment response and adverse effects rather than evaluated in isolation.
Planning does not focus only on whether a tumor shrinks. It also considers disease control, the possibility of eliminating microscopic cancer cells, symptom relief, and the adverse effects produced by treatment. Reviewing these outcomes together helps align the selected medicines, doses, schedules, and combinations with the intended therapeutic goal.
After surgery, systemic chemotherapy may be used to eliminate microscopic cancer cells that remain even when the visible tumor has been removed. Its purpose in this setting differs from treating an obvious mass: the emphasis is reducing residual disease that may be difficult to detect, supporting disease control after surgery.
Systemic chemotherapy can serve several goals depending on the clinical situation. It may shrink tumors, control disease, or relieve symptoms when cancer is advanced. These goals show that treatment is not limited to eliminating every malignant cell; reducing tumor burden or controlling disease can also be meaningful outcomes in medicine.
Treatment can be delivered orally or intravenously, so administration is incorporated into the regimen alongside drug selection and dosing schedules. The route is a practical part of how medicines enter systemic treatment, while the broader plan still depends on the intended goal, expected response, and adverse effects.